CoChat

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

Open access

The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.

Abstract

Introduction: PROOF (a Prospective Observational Registry to Describe the Disease Course and Outcomes of Idiopathic Pulmonary Fibrosis) is an ongoing, observational registry initiated in 2013 with the aim of collecting real-world data from patients with idiopathic pulmonary fibrosis (IPF). Here, we present comprehensive baseline data, which were collected from patients on registry inclusion. Methods: Patients with IPF were enrolled across eight centres in Belgium and Luxembourg. Baseline data collected included demographics, diagnostic information and clinical characteristics, including lung function and health-related quality of life. Data on comorbidities and prescribed medication were also collected. Results: A total of 277 patients were enrolled in the PROOF registry. At inclusion, 92.8% and 6.5% of patients had a definite or probable diagnosis of IPF, respectively. Mean per cent predicted forced vital capacity and carbon monoxide diffusing capacity were 80.6% and 46.9%, respectively. Mean St. George’s Respiratory Questionnaire total score was 47.0, and mean Cough-Visual Analogue Scale score was 30.5 mm. The most prevalent comorbidities reported at inclusion were gastrointestinal disorders (50.2%), including gastro-oesophageal reflux disease (47.3%) and metabolism and nutrition disorders (39.7%). At inclusion, 67.2% and 2.2% of patients were prescribed pirfenidone and nintedanib, respectively, with treatment initiated either prior to, or at the time of, inclusion. Medication prescribed concomitantly with pirfenidone included antihypertensives (54.8%), statins (37.1%) and prophylactic antithrombotics/anticoagulants (36.6%). Conclusion: The PROOF registry provides valuable demographic and clinical data from a real-world population of patients with IPF in Belgium and Luxembourg, demonstrating the high burden of comorbidities and prescribed medication in these patients. Longitudinal data from this patient population will be investigated in future analyses. Trial registration: PROOF is registered with the relevant authorities in Belgium and Luxembourg, with registration to Comité National d’Éthique et de Recherché (CNER) N201309/03 – 12 September 2013 and a notification to Comité National de Protection des Données (CNDP).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjresp-2018-000331

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Proportion of patients reporting problems across each dimension of the EQ-5D at registry inclusion. EQ-5D, EuroQol-5 Dimensions Health Questionnaire.
Figure 1 Proportion of patients reporting problems across each dimension of the EQ-5D at registry inclusion. EQ-5D, EuroQol-5 Dimensions Health Questionnaire.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 3

  1. King TE , Bradford WZ , Castro-Bernardini S . The ASCEND study: a randomized, double-blind, placebo controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). American Thoracic Society International Conference, 2014.
  2. Wuyts W , Dahlqvist C , Slabbynck H . Demographics and healthcare utilization of patients with idiopathic pulmonary fibrosis (IPF) in a real-world setting: updated findings from 277 patients in the PROOF registry. Abstract A1127. American Thoracic Society International Conference, 2017.
  3. Flaherty K , de Andrade J , Chou W . Baselinecharacteristics of the initial 200 participants in the Pulmonary Fibrosis Foundation Registry. Abstract A24. American Thoracic Society International Conference, 2017.

Cited by

See all 56

Metadata

Authors
Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compere, C., Maddens, S., Kirchgaessler, K.-U., Bartley, K., & Bondue, B.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • CHU Dinant Godinne UCL Namur (BE)
  • ZNA Middelheim Hospital (BE)
  • Centre Hospitalier de Luxembourg (LU)
  • Centre hospitalier régional de la Citadelle (BE)
  • CHIREC Hospital, Brussels, Belgium
  • AZ Groeninge (BE)
  • F. Hoffmann-La Roche AG (CH)
  • Genentech (US)
  • Erasmus Hospital (BE)
Corresponding author
Wuyts, Wim A
Venue
BMJ Open Respiratory Research
Publisher
BMJ
Published
2018-11
Volume
5
Issue
1
Pages
e000331
ISSN
2052-4439 (ISSN-L)
OpenAlex
W2900996054
Cited by
54
References
36
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 13 · 2021: 7 · 2020: 14 · 2019: 5
FWCI
4.90
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open Respiratory Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
Funders
Genentech, Inc. and F. Hoffmann-La Roche, Ltd.
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, comorbidities, prescription drugs, pirfenidone, nintedanib, lung function, health-related quality of life, gastroesophageal reflux disease, disease burden, real-world data, Belgium, Luxembourg, statins, antihypertensive drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. https://app.cochat.ai/papers/10.1136/bmjresp-2018-000331
The paper
Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compere, C., Maddens, S., Kirchgaessler, K.-U., Bartley, K., & Bondue, B. (2018). Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. BMJ Open Respiratory Research. https://doi.org/10.1136/bmjresp-2018-000331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.